We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.92 | -2.27% | 39.61 | 39.43 | 39.98 | 39.87 | 39.56 | 39.76 | 1,597,055 | 22:00:00 |
From Feb 2023 to Feb 2025
By Giulia Petroni
Roche said that its Elecsys IL-6 test was approved in countries carrying the "CE" safety mark to help diagnose neonatal sepsis, one of the leading causes of death in newborns.
Neonatal sepsis is an infection involving the bloodstream within the first four weeks of life, and can rapidly progress to multisystem organ failure. An early diagnosis can potentially decrease mortality rates and mitigate long-term consequences, the Swiss pharmaceutical giant said Wednesday.
Elecsys IL-6, which is used to identify severe inflammatory responses in patients, takes 18 minutes to run and only a small amount of blood, Roche said.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
October 18, 2023 01:39 ET (05:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
